Camac Fund, LP, Insider at Pasithea Therapeutics Corp. (KTTA), bought 144,547 shares at $1.13 ($163K) on 2022-09-01, disclosed to the SEC on 2022-09-06.
Open-market purchase of $163k KTTA by Insider. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.13 | 55,646 | $63K | 38.5% |
| 2 | $1.13 | 55,646 | $63K | 38.5% |
| 3 | $1.14 | 11,507 | $13K | 8.0% |
| 4 | $1.13 | 21,748 | $25K | 15.0% |
| Total | $1.13 avg | 144,547 | $163K | 100% |
| Filing → |
| ABCP | SELL | 2024-02-20 | $1.4M | — | Filing → |
| ABCP | SELL | 2023-10-11 | $8K | — | Filing → |
| ABCP | SELL | 2023-09-26 | $11K | — | Filing → |